Канал: Genitourinary Cancers

What do we need to accomplish to cure GU malignancies by 2025? - Dean Bajorin

What do we need to accomplish to cure GU malignancies by 2025? - Dean Bajorin

How do I treat CRPC in 2015? - Oliver Sartor

How do I treat CRPC in 2015? - Oliver Sartor

How do I treat metastatic RCC in 2015? - Charles J. Ryan

How do I treat metastatic RCC in 2015? - Charles J. Ryan

How do I treat advanced bladder cancer in 2015? - Walter Stadler

How do I treat advanced bladder cancer in 2015? - Walter Stadler

The next step in immunotherapy for GU malignancies - Allan J. Pantuck

The next step in immunotherapy for GU malignancies - Allan J. Pantuck

Personalizing therapy for GU tumors - Alan Bryce

Personalizing therapy for GU tumors - Alan Bryce

Addressing the needs of GU cancer survivors - Deborah Kuban

Addressing the needs of GU cancer survivors - Deborah Kuban

New surgical techniques - Jennifer A. Linehan

New surgical techniques - Jennifer A. Linehan

Molecular genomics of prostate cancer - Scott A. Tomlins

Molecular genomics of prostate cancer - Scott A. Tomlins

Biologic rationale for next-generation AR inhibitors - Mary-Ellen Taplin

Biologic rationale for next-generation AR inhibitors - Mary-Ellen Taplin

Abiraterone: Prolonging survival pre-docetaxel - Charles J. Ryan

Abiraterone: Prolonging survival pre-docetaxel - Charles J. Ryan

Enzalutamide: Monotherapy and combination therapy - Andrew J. Armstrong

Enzalutamide: Monotherapy and combination therapy - Andrew J. Armstrong

What to do with the post-abiraterone/-enzalutamide patient? - Nicholas J. Vogelzang

What to do with the post-abiraterone/-enzalutamide patient? - Nicholas J. Vogelzang

Next-generation anti-androgen therapy: ARN-509 and ODM-201 - Emmanuel Antonarakis

Next-generation anti-androgen therapy: ARN-509 and ODM-201 - Emmanuel Antonarakis

New strategies to overcome resistance to current therapies in prostate cancer - Anna C. Ferrari

New strategies to overcome resistance to current therapies in prostate cancer - Anna C. Ferrari

9:45 AM Radium-223: How can we optimize the use for metastatic CRPC? - Tanya B. Dorff

9:45 AM Radium-223: How can we optimize the use for metastatic CRPC? - Tanya B. Dorff

Radium-223 combinations: Choosing a companion drug - Oliver Sartor

Radium-223 combinations: Choosing a companion drug - Oliver Sartor

Next advances in radiotherapy for prostate cancer - Seungtaek Choi

Next advances in radiotherapy for prostate cancer - Seungtaek Choi

Prolonging survival in early chemo-sensitive populations - Christopher Sweeney

Prolonging survival in early chemo-sensitive populations - Christopher Sweeney

Does every patient need hormonal ablation? - Walter Stadler

Does every patient need hormonal ablation? - Walter Stadler

Oligometastatic disease: What do we do now? - Oliver Sartor

Oligometastatic disease: What do we do now? - Oliver Sartor

A randomized, phase II trial of docetaxel and prednisone - Daniel Silbiger

A randomized, phase II trial of docetaxel and prednisone - Daniel Silbiger

Accumulation of cancer-associated fibroblasts contributes to bladder cancer - Woonyoung Choi

Accumulation of cancer-associated fibroblasts contributes to bladder cancer - Woonyoung Choi

Use of radium-223 with chemotherapy-naïve metastatic prostate cancer - Hamid Emamekhoo

Use of radium-223 with chemotherapy-naïve metastatic prostate cancer - Hamid Emamekhoo

INO-5150: A PSA- and PSMA-DNA based vaccine for prostate - Zane Yang

INO-5150: A PSA- and PSMA-DNA based vaccine for prostate - Zane Yang

Avatar: In vitro modeling of in vivo microenvironments - James Lim

Novel minibodies to evaluate molecular targets - Robert Reiter

Novel minibodies to evaluate molecular targets - Robert Reiter

How do I maintain active surveillance? - Mitchell E. Gross

How do I maintain active surveillance? - Mitchell E. Gross

5:00 PM Therapeutic vaccines: The right targets at the right times - Douglas G. McNeel

5:00 PM Therapeutic vaccines: The right targets at the right times - Douglas G. McNeel

Moving Provenge to the next level - Tanya B. Dorff

Moving Provenge to the next level - Tanya B. Dorff

Overcoming resistance to ADT: What comes next? - Anna C. Ferrari

Overcoming resistance to ADT: What comes next? - Anna C. Ferrari

PARP and DNA repair defects (BRCA mutations) - Karen E. Knudsen

PARP and DNA repair defects (BRCA mutations) - Karen E. Knudsen

HDAC inhibitors: What do we know and where do we go? - Wm. Keving Kelly

HDAC inhibitors: What do we know and where do we go? - Wm. Keving Kelly

AR-V7 as a biomarker to identify ADT-resistant patients - Emmanuel Antonarakis

AR-V7 as a biomarker to identify ADT-resistant patients - Emmanuel Antonarakis

Bipolar androgen therapy - John T. Isaacs

Bipolar androgen therapy - John T. Isaacs

Biology of neuroendocrine differentiation - Jiaoti Huang

Biology of neuroendocrine differentiation - Jiaoti Huang

How do I approach NEPC? - Andrew J. Armstrong

How do I approach NEPC? - Andrew J. Armstrong

Novel imaging techniques - Robert Reiter

Novel imaging techniques - Robert Reiter